Emerging drugs for the treatment of erectile dysfunction

Bibliography

• Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7(11):3572-88
   PubMed Web of Science ®Google Scholar
• Lue TF. Erectile dysfunction. N Engl J Med 2000;342(24):1802-13
   PubMed Web of Science ®Google Scholar
• Porst H, Sharlip ID. History and epidemiology of male sexual dysfunction. In: Porst H, Buvat J, editors. The Standards Committee of the International Society for Sexual Medicine. Standards Committee of the International Society for Sexual Medicine. Blackwell Publishing Ltd; Oxford, UK: 2006
   Google Scholar
• Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000;12(6):305-11
   PubMed Web of Science ®Google Scholar
• Kumamoto Y, Tsukamoto T, Satoh T, et al. Epidemiological study on aging changes of sexual activity in japanese men and women. Aging Male 2000;3(suppl 1):9
   Google Scholar
• Cronenwett J, Johnston K. Erectile dysfunction. In: Cronenwett JL, Wayne Johnston K, editors. Rutherford’s vascular surgery. 8th edition. Saunders; Philadelphia, PA: 2014. p. 1208-20
   Google Scholar
• Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7(1 Pt 2):524-40
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57(5):804-14
   PubMed Web of Science ®Google Scholar
• Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92:9a-9m-18m
   PubMed Web of Science ®Google Scholar
• Berner MM, Kriston L, Harms A. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res 2006;18(3):229-35
   PubMed Web of Science ®Google Scholar
• Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008;4(6):1315-30
   PubMedGoogle Scholar
• Mochida H, Yano K, Inoue H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. J Urol 2013;190(2):799-806
   PubMed Web of Science ®Google Scholar
• Goldstein I, Jones LA, Belkoff LH, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc 2012;87(9):843-52
   PubMed Web of Science ®Google Scholar
• Morales AM, Casillas M, Turbi C. Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature. Int J Impot Res 2011;23(1):1-8
   PubMed Web of Science ®Google Scholar
• Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother 2014;15(3):421-8
   PubMed Web of Science ®Google Scholar
• Godschalk MF, Chen J, Katz PG, et al. Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol 1994;151(6):1530-2
   PubMed Web of Science ®Google Scholar
• Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996;155(3):802-15
   PubMed Web of Science ®Google Scholar
• Heaton JP, Lording D, Liu SN, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001;13(6):317-21
   PubMed Web of Science ®Google Scholar
• Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine 2004;23(2-3):149-55
   PubMed Web of Science ®Google Scholar
• Sandhu D, Curless E, Dean J, et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999;11(2):91-7
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 1999;83(3):274-9
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int 2008;102(8):933-7
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabe A, Cheliz G, et al. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol 1996;155(3):913-14
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabe A, Cheliz G, et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol 1997;157(6):2132-4
   PubMed Web of Science ®Google Scholar
• Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160(6 Pt 1):2041-6
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000;55(1):109-13
   PubMed Web of Science ®Google Scholar
• Filippi S, Luconi M, Granchi S, et al. Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation. Int J Impot Res 2002;14(4):295-307
   PubMed Web of Science ®Google Scholar
• Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159(2):433-6
   PubMed Web of Science ®Google Scholar
• Ledda A, Belcaro G, Cesarone MR, et al. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int 2010;106(7):1030-3
   PubMed Web of Science ®Google Scholar
• Chen J, Wollman Y, Chernichovsky T, et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 1999;83(3):269-73
   PubMed Web of Science ®Google Scholar
• Maclennan KM, Boshier A, Wilton LV, Shakir SA. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 2006;98(1):125-31
   PubMed Web of Science ®Google Scholar
• Sopko NA, Hannan JL, Bivalacqua TJ. Understanding and targeting the Rho kinase pathway in erectile dysfunction. Nat Rev Urol 2014;11(11):622-8
   PubMed Web of Science ®Google Scholar
• Costa C, Soares R, Castela A, et al. Increased endothelial apoptotic cell density in human diabetic erectile tissue--comparison with clinical data. J Sex Med 2009;6(3):826-35
   PubMed Web of Science ®Google Scholar
• Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 2009;6(8):415-27
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med 2007;4(3):538-43
   PubMed Web of Science ®Google Scholar
• Traish AM, Munarriz R, O’Connell L, et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24(3):381-7
   PubMed Web of Science ®Google Scholar
• Hull EM, Eaton RC, Markowski VP, et al. Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: implications for copulation. Life Sci 1992;51(22):1705-13
   PubMed Web of Science ®Google Scholar
• Melis MR, Stancampiano R, Gessa GL, et al. Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: site of action in the brain. Neuropsychopharmacology 1992;6(1):17-21
   PubMed Web of Science ®Google Scholar
• de Groat WC, Booth A. Neural control of penile erection. In: Maggi CA, editor. The autonomic nervous system. Harwood, London; 1993. p. 465-513
   Google Scholar
• Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75(1):191-236
   PubMed Web of Science ®Google Scholar
• Gelez H, Poirier S, Facchinetti P, et al. Neuroanatomical evidence for a role of central melanocortin-4 receptors and oxytocin in the efferent control of the rodent clitoris and vagina. J Sex Med 2010;7(6):2056-67
   PubMed Web of Science ®Google Scholar
• Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002;99(17):11381-6
   PubMed Web of Science ®Google Scholar
• Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32(4):379-95, v
   PubMed Web of Science ®Google Scholar
• Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, et al. Campbell-Walsh Urology. 10th editon. WB Saunders Co; Philadelphia: 2012. p. 688-720
   Google Scholar
• Dai Y, Zhang Y, Phatarpekar P, et al. Adenosine signaling, priapism and novel therapies. J Sex Med 2009;6(Suppl 3):292-301
   PubMedGoogle Scholar
• Johnson DA, Akamine P, Radzio-Andzelm E, et al. Dynamics of cAMP-dependent protein kinase. Chem Rev 2001;101(8):2243-70
   PubMed Web of Science ®Google Scholar
• Simonsen U, Prieto D, Hernandez M, et al. Adrenoceptor-mediated regulation of the contractility in horse penile resistance arteries. J Vasc Res 1997;34(2):90-102
   PubMed Web of Science ®Google Scholar
• Okon EB, Szado T, Laher I, et al. Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 2003;40(6):520-30
   PubMed Web of Science ®Google Scholar
• Rees RW, Ziessen T, Ralph DJ, et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002;14(1):1-7
   PubMed Web of Science ®Google Scholar
• Ito M, Nakano T, Erdodi F, et al. Myosin phosphatase: structure, regulation and function. Mol Cell Biochem 2004;259(1-2):197-209
   PubMed Web of Science ®Google Scholar
• Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 2007;292(6):H2598-606
   PubMed Web of Science ®Google Scholar
• Large WA. Receptor-operated Ca2(+)-permeable nonselective cation channels in vascular smooth muscle: a physiologic perspective. J Cardiovasc Electrophysiol 2002;13(5):493-501
   PubMed Web of Science ®Google Scholar
• Fan SF, Brink PR, Melman A, et al. An analysis of the Maxi-K+ (KCa) channel in cultured human corporal smooth muscle cells. J Urol 1995;153(3 Pt 1):818-25
   PubMed Web of Science ®Google Scholar
• Christ GJ, Spray DC, Brink PR. Characterization of K currents in cultured human corporal smooth muscle cells. J Androl 1993;14(5):319-28
   PubMed Web of Science ®Google Scholar
• Bivalacqua TJ, Hellstrom WJ. Potential application of gene therapy for the treatment of erectile dysfunction. J Androl 2001;22(2):183-90
   PubMed Web of Science ®Google Scholar
• Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006;17(12):1165-76
   PubMed Web of Science ®Google Scholar
• Damle B, Duczynski G, Jeffers BW, et al. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther 2014;36(2):236-44
   PubMed Web of Science ®Google Scholar
• Doh H, Shin CY, Son M, et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2002;25(6):873-8
   PubMed Web of Science ®Google Scholar
• Moon du G, Yang DY, Lee CH, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med 2011;8(7):2048-61
   PubMed Web of Science ®Google Scholar
• Paick JS, Kim SW, Park YK, et al. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sex Med 2009;6(11):3166-76
   PubMed Web of Science ®Google Scholar
• Chung BH, Lee JY, Lee SH, et al. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009;21(2):122-8
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60(2):380-7
   PubMed Web of Science ®Google Scholar
• Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl- 3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom 2007;21(7):1139-49
   PubMed Web of Science ®Google Scholar
• Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5(11):2672-80
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho SY, Oh CY, et al. Efficacy and safety of combination therapy with mirodenafil and alpha1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res 2011;23(6):249-56
   PubMed Web of Science ®Google Scholar
• Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009;6(2):553-7
   PubMed Web of Science ®Google Scholar
• Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7(5):1928-36
   PubMed Web of Science ®Google Scholar
• Smith WB2nd, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract 2013;67(8):768-80
   PubMed Web of Science ®Google Scholar
• Sweetnam P, Campbell S, Grogan M, et al. SLx-2101, a novel long-acting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: in vivo and in vitro studies [abstract no. 51]. J Sex Med 2006;3(suppl):29-30
   Google Scholar
• SLx-2101; Pharmaprojects-copyright to citeline drug intelligence (an informa business)
   Google Scholar
• Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res 2000;12(Suppl 4):S74-9
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16(1):51-9
   PubMed Web of Science ®Google Scholar
• Hellstrom W, Gittelman M, Zinner N, et al. Randomized, double-blind, placebo-controlled, at-home study to evaluate the efficacy and safety of intranasal bremelanotide in men with erectile dysfunction with and without diabetes mellitus [abstract]. 9th Congress of the European Society for Sexual Medicine; Vienna, Austria; J Sex Med 2006. p. 117
   Google Scholar
• Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179(3):1066-71
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Garcia WD, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 2005;65(4):755-9
   PubMed Web of Science ®Google Scholar
• Cowart M, Latshaw SP, Bhatia P, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem 2004;47(15):3853-64
   PubMed Web of Science ®Google Scholar
• Brioni JD, Moreland RB, Cowart M, et al. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci USA 2004;101(17):6758-63
   PubMed Web of Science ®Google Scholar
• Patel MV, Kolasa T, Mortell K, et al. Discovery of 3-methyl-N-(1-oxy-3’,4’,5’,6’-tetrahydro-2’H-[2,4’-bipyridine]-1’-ylmethyl)benzam ide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem 2006;49(25):7450-65
   PubMed Web of Science ®Google Scholar
• Chan JS, Kim DJ, Ahn CH, et al. Clavulanic acid stimulates sexual behaviour in male rats. Eur J Pharmacol 2009;609(1-3):69-73
   PubMed Web of Science ®Google Scholar
• Rexahn Pharmaceuticals, Inc. Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED). National Library of Medicine (US). ClinicalTrials.gov; Bethesda (MD): 2009
   Google Scholar
• Oudot A, Behr-Roussel D, Poirier S, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol 2011;60(5):1020-6
   PubMed Web of Science ®Google Scholar
• Albersen M, Linsen L, Tinel H, et al. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med 2013;10(5):1268-77
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare AG. A prospective, randomized, double-blind, double-dummy, placeboand active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552/ vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors. National Library of Medicine (US), ClinicalTrials.gov; Bethesda (MD): 2014
   Google Scholar
• Buyukafsar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003;472(3):235-8
   PubMed Web of Science ®Google Scholar
• Li WJ, Park K, Paick JS, et al. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J Sex Med 2011;8(2):400-10
   PubMed Web of Science ®Google Scholar
• Saito A, Inoue M, Kon H, et al. Effectiveness of intraarterial administration of fasudil hydrochloride for preventing symptomatic vasospasm after subarachnoid hemorrhage. Acta Neurochir Suppl 2015;120:297-301
   PubMedGoogle Scholar
• Otsuka T, Ibuki C, Suzuki T, et al. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis 2008;19(2):105-10
   PubMed Web of Science ®Google Scholar
• Lasker GF, Maley JH, Kadowitz PJ. A review of the pathophysiology and novel treatments for erectile dysfunction. Adv Pharmacol Sci 2010;2010; pii: 730861
   PubMedGoogle Scholar
• Guagnini F, Ferazzini M, Grasso M, et al. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med 2012;10:59
   PubMed Web of Science ®Google Scholar
• Sanofi-Avenis. Randomized, double-blind, placebo and active controlled study of the activity of SAR407899 single-dose on the ability to increase duration of penile rigidity, under experimental condition, in patients with mild to moderate erectile dysfunction. National Library of Medicine: ClinicalTrials.gov, Bethesda (MD; 2009
   Google Scholar
• Bentzen BH, Olesen SP, Ronn LC, et al. BK channel activators and their therapeutic perspectives. Front Physiol 2014;5:389
   PubMed Web of Science ®Google Scholar
• Kun A, Matchkov VV, Stankevicius E, et al. NS11021, a novel opener of large-conductance Ca(2+)-activated K(+) channels, enhances erectile responses in rats. Br J Pharmacol 2009;158(6):1465-76
   PubMed Web of Science ®Google Scholar
• Kiraly I, Pataricza J, Bajory Z, et al. Involvement of large-conductance Ca(2+) -activated K(+) channels in both nitric oxide and endothelium-derived hyperpolarization-type relaxation in human penile small arteries. Basic Clin Pharmacol Toxicol 2013;113(1):19-24
   PubMed Web of Science ®Google Scholar
• Bang WJ, Oh CY, Yoo C, et al. Efficacy and saftey of the simulatneous administration of mirodenafil and an alpha-blocker in men with BPH-LUTS: a multicenter open-label prospective study. In J Impot Res 2013;25(4):149-54
   PubMed Web of Science ®Google Scholar